Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera
- PMID: 15102479
- DOI: 10.1016/j.exphem.2003.11.003
Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera
Abstract
Polycythemia vera (PV) is a myeloproliferative disorder arising in a multipotent hematopoietic stem cell. The pathogenesis of PV remains poorly understood; however, the biologic hallmark of this disease is the presence of erythropoietin (Epo)-independent colony formation (endogenous erythroid colony [EEC]) and cytokine hypersensitivity. We have developed a simple liquid culture from CD34+ cells to study PV erythroid differentiation. PV erythroid differentiation was characterized in this culture system by two types of abnormalities: 1) an increased proliferation of progenitors in response to cytokines, associated with strict cytokine dependency for preventing apoptosis; and 2) Epo-independent terminal erythroid differentiation in the presence of stem cell factor and interleukin-3 as evidenced by the acquisition of glycophorin A. The level of Epo-independent terminal differentiation correlates in PV patients with the number of EEC. Epo-independent terminal differentiation as well as normal Epo-induced differentiation were repressed by inhibitors of JAK2 (AG490), PI3K (LY294002), and the Src family kinases (PP2). In contrast, an inhibitor of the ERK/MAP kinase pathway (PD98059) had no effect on Epo-independent terminal differentiation. These signaling abnormalities were not mediated by a decreased expression or activity of the membrane tyrosine phosphatase CD45, which dephosphorylates JAK2 and Src family kinases. This study demonstrates that early steps of PV erythroid differentiation are strictly cytokine dependent. In contrast, late erythroid differentiation is an Epo-independent phenomenon that is mediated by signaling pathways identical to those in Epo-induced differentiation.
Similar articles
-
Erythropoietin-independent erythroid colony formation by bone marrow progenitors exposed to interleukin-11 and interleukin-8.Exp Hematol. 2005 Nov;33(11):1299-308. doi: 10.1016/j.exphem.2005.07.002. Exp Hematol. 2005. PMID: 16263414
-
Neutralization of autocrine transforming growth factor-beta in human cord blood CD34(+)CD38(-)Lin(-) cells promotes stem-cell-factor-mediated erythropoietin-independent early erythroid progenitor development and reduces terminal differentiation.Stem Cells. 2003;21(5):557-67. doi: 10.1634/stemcells.21-5-557. Stem Cells. 2003. PMID: 12968110
-
Recombinant human mast cell growth factor supports erythroid colony formation in polycythemia vera in the presence and absence of erythropoietin and serum.Exp Hematol. 1993 Sep;21(10):1353-7. Exp Hematol. 1993. PMID: 7689483
-
Polycythemia and oxygen sensing.Pathol Biol (Paris). 2004 Jun;52(5):280-4. doi: 10.1016/j.patbio.2004.02.006. Pathol Biol (Paris). 2004. PMID: 15217714 Review.
-
Pathogenesis of polycythemia vera.Haematologica. 1998 Feb;83(2):150-8. Haematologica. 1998. PMID: 9549927 Review.
Cited by
-
Genetics of myeloproliferative neoplasms.Cancer J. 2014 Jan-Feb;20(1):61-5. doi: 10.1097/PPO.0000000000000013. Cancer J. 2014. PMID: 24445766 Free PMC article. Review.
-
Nosocomial Co-Transmission of Avian Influenza A(H7N9) and A(H1N1)pdm09 Viruses between 2 Patients with Hematologic Disorders.Emerg Infect Dis. 2016 Apr;22(4):598-607. doi: 10.3201/eid2204.151561. Emerg Infect Dis. 2016. PMID: 26982379 Free PMC article.
-
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.PLoS One. 2013;8(1):e54826. doi: 10.1371/journal.pone.0054826. Epub 2013 Jan 31. PLoS One. 2013. PMID: 23382981 Free PMC article.
-
Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.Blood Cancer J. 2011 Jul;1(7):e29. doi: 10.1038/bcj.2011.29. Epub 2011 Jul 22. Blood Cancer J. 2011. PMID: 22829185 Free PMC article.
-
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.Clin Cancer Res. 2013 Apr 15;19(8):1933-40. doi: 10.1158/1078-0432.CCR-12-0284. Epub 2013 Feb 13. Clin Cancer Res. 2013. PMID: 23406773 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous